Skip to main content

BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Secures ~$9M in Public Offering

Panbela (NASDAQ: PBLA) is a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company today announced the closing of its public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “public warrants”) at a purchase price of $2.06 per share and associated public warrants and $2.059 per pre-funded warrant and associated public warrants. Panbela secured approximately $9.0 million in gross proceeds from the offering, of which it intends to use the net for the continued clinical development of its product candidates, working capital, business development and other general corporate purposes, which may include repayment of debt. Roth Capital Partners acted as sole placement agent of the offering.

To view the full press release, visit

About Panbela Therapeutics Inc.

Panbela is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (“SBP-101”) and Flynpovi. Further information can be found at Panbela’s common stock is listed on the Nasdaq Stock Market LLC under the symbol PBLA.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.